FDA Awards More Than $16 Million to Support Rare Disease Research
The FDA has awarded more than $16 million to six academic and industry research institutions to help finance clinical trials for rare disease treatments.
The agency awarded these grants following a review of 47 clinical trial grant applications by more than 90 clinical trial and rare disease experts.
Recipients of these grants include Acucela, which will receive $1.6 million over three years for a phase 3 study of emixustat hydrochloride to treat Stargardt disease. The Fred Hutchinson Cancer Research center will receive $3.5 million over four years for its phase 2 study of ustekinumab for preventing graft vs. host disease.
Additional grants include $3 million to support Seattle Children’s Hospital’s phase 1b cystic fibrosis study over a four-year period, $3.1 million for State University of New York Stony Brook’s phase 1 CD4 positive T cell neoplasm study, $1.9 million for a University of Cincinnati phase 1/2 pancreatic cancer study and $3.2 million to support a University of Virginia phase 2 T cell lymphoma study.